BCG-unresponsive NMIB Archives

News

Ferring Pharmaceuticals and SK pharmteco Enter into Commercial Gene Therapy Manufacturing Deal

April 18, 2024
Bob Brousseau
Posted in News
active pharmaceutical ingredients, Adstiladrin®, APIs, BCG-unresponsive NMIB, bladder cancer, cancer therapy, CDMO, cell and gene therapy, CGMP, Ferring Pharmaceuticals, intravesical gene therapy, nadofaragene firadenovec-vncg, non-muscle invasive bladder cancer, sk pharmteco

Biopharmaceutical contract manufacturer SK pharmteco commits to production, testing, and release of Ferring’s U.S. approved Adstiladrin® (nadofaragene firadenovec-vncg) The deal...